The Technical Analyst
Pluristem Therapeutics [PSTI]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Pluristem Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.91% $1.000
/ 26 jul 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 40.85 mill |
| EPS: | -1.462 |
| P/E: | -0.684 |
| Earnings Date: | Sep 12, 2022 |
| SharesOutstanding: | 40.85 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2022-09-26 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.684 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.684 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.896 - 1.104 ( +/- 10.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-10 | Aberman Zami | Buy | 80 616 | Common Stock |
| 2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 122 663 | Common Stock |
| 2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 22 015 | Common Stock |
| 2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 71 775 | Common stock |
| 2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 24 110 | Common stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 98 transactions |
| Buy: 11 245 290 | Sell: 1 084 851 |
Forecast:
01:40 - $1.013
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.000 (-2.91% ) |
| Volume | 0.171 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PSTI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PSTI
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Last 10 Buy Signals
Latest Press Releases
2021-09-22 08:15:00 - Press Release
Pluristem Ceo Issues Shareholder Update
Haifa, israel, sept. 22, 2021 (globe newswire) -- pluristem therapeutics inc. (nasdaq: psti) (tase: psti), a leading biotechnology company, today issued an update to its shareholders from its chief executive officer and president yaky yanay.
2021-07-19 07:00:00 - Press Release
Pluristem Appoints Prof. Varda Shalev Md And Mr.
Haifa, israel, july 19, 2021 (globe newswire) -- pluristem therapeutics inc. (nasdaq: psti) (tase: psti), a leading biotechnology company, today announced the board of director appointments of prof. varda shalev, a physician, medical researcher, and professor of medicine at the tel aviv university's school of public health, and mr. doron birger, a high-tech industry executive with a background in bringing groundbreaking products to market.
2021-07-08 07:10:00 - Press Release
Pluristem Brings Ards Associated With Covid-19 Phase Ii Studies To Clinical Readout
Haifa, israel, july 08, 2021 (globe newswire) -- pluristem therapeutics inc. (nasdaq:psti) (tase:psti) (the “company”), a leading biotechnology company announced today that it is bringing its acute respiratory distress syndrome (ards) associated with covid-19 phase ii studies to clinical readout. the company's covid-19 program included over 100 patients across two phase ii studies in the u.s., europe and israel, and in compassionate use and expanded access programs in the u.s. and israel. the analysis will be based on 89 patients enrolled in the previously announced two phase ii studies, which investigated the safety and efficacy of pluristem's plx cells as a treatment for severe covid-19 cases complicated by ards.
2021-02-02 08:30:00 - Press Release
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
Haifa, israel, feb. 02, 2021 (globe newswire) -- pluristem therapeutics inc. (nasdaq:psti) (tase:psti), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“pluristem” or the “company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million before deducting placement agent fees and expenses. the closing of the offering is expected to occur on or about february 4, 2021, subject to the satisfaction of customary closing conditions.
2020-12-29 07:00:00 - Press Release
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&d To Expand Pluristem's Ards Associated With Covid-19 Program To Mexico
Haifa, israel, dec. 29, 2020 (globe newswire) -- pluristem therapeutics inc. (nasdaq:psti) (tase:psti), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with mexican pharmaceutical company innovare r&d to expand its ongoing clinical program of plx cells in the treatment of acute respiratory distress syndrome (ards) associated with covid-19 in mexico. the phase ii study in mexico is subject to the approval of local authorities, with the goal of being conducted under the u.s. food and drug administration (fda) cleared protocol .
Latest News
2022-07-14 12:24:04 - Zacks Investment Research
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
2022-07-13 09:59:02 - Benzinga
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short.
2022-01-22 11:30:00 - PennyStocks
Best Penny Stocks to Buy as January Ends? 4 to Watch
Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-10 10:38:56 - PennyStocks
Best Penny Stocks to Buy Right Now? 3 For Your List in January
Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-10 06:26:32 - Benzinga
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products.
2021-12-28 13:48:12 - Zacks Investment Research
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
2021-09-22 08:15:00 - GlobeNewsWire
Pluristem CEO Issues Shareholder Update
HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.
2021-07-19 07:00:00 - GlobeNewsWire
Pluristem Appoints Prof. Varda Shalev MD and Mr.
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market.
2021-07-08 07:10:00 - GlobeNewsWire
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout. The Company's COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem's PLX cells as a treatment for severe COVID-19 cases complicated by ARDS.
2021-06-05 07:53:36 - 24/7 Wall Street
Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 194,000 shares of Pluristem Therapeutics Inc.